# US 9,434,920 B2 · Defined media for expansion and maintenance of pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,434,920 B2
- Document ID: US9434920B2
- Status: Granted
- Kind: B2
- Application number: 13/787,173
- Filed: 2013-03-06
- Published: 2013-09-12
- Granted: 2016-09-06
- Earliest claimed: 2012-03-07
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Alireza Rezania
- Web page: https://patentgrep.com/patent/US9434920B2

## CPC

- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 2500/05: Inorganic components
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2500/34: Sugars
- C12N 2500/36: Lipids
- C12N 2500/38: Vitamins
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods to promote the proliferation of undifferentiated pluripotent stem cells in defined media. Specifically, the invention provides a defined cell culture formulation for the culture, maintenance, and expansion of pluripotent stem cells, wherein culturing stem cells in the defined cell culture formulation maintains the pluripotency and karyotypic stability of the cells for at least 10 passages. Further disclosed is a cell population grown under defined media conditions that express OCT4, SOX2, NANOG, and FOXA2.

## Claims

### Claim 1

A method for the expansion of human pluripotent stem cells comprising culturing the human pluripotent stem cells on a feeder-free matrix in a defined cell culture formulation to thereby expand the cells,
wherein the defined cell culture formulation consists essentially of DMEM-F12 basal medium, insulin, transferrin, selenium, fatty-acid free albumin, from about 5 ng/ml to about 10 ng/ml of a TGF-β ligand, from about 50 ng/ml to about 100 ng/ml of bFGF, insulin growth factor 1 (IGF-1) and ascorbic acid,
wherein culturing the human pluripotent stem cells in the defined cell culture formulation maintains the pluripotency and karyotypic stability of the cells for at least 10 passages,
and wherein at least 80% of the cells express CD9 at five passages beyond passage 15.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TGF-β ligand is TGF-β1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the fatty acid free albumin is reagent grade.

### Claim 4 (depends on 1)

The method of claim 1, wherein the defined culture formulation consists essentially of DMEM-F12 basal medium, insulin, transferrin, selenium, from about 0.2% to about 2.5% of fatty-acid free albumin, from about 5 ng/ml to about 10 ng/ml of a TGF-β ligand, from about 50 ng/ml to about 100 ng/ml of bFGF, from about 10 ng/ml to about 50 ng/ml of IGF-1 and from about 0.2 mM to about 0.3 mM of ascorbic acid.

### Claim 5 (depends on 1)

The method of claim 1, wherein the defined culture formulation consists of DMEM-F12 basal medium, insulin, transferrin, selenium, fatty-acid free albumin, from about 5 ng/ml to about 10 ng/ml of a TGF-β ligand, from about 50 ng/ml to about 100 ng/ml of bFGF, insulin growth factor 1 (IGF-1) and ascorbic acid.

### Claim 6 (depends on 1)

The method of claim 1, wherein the defined culture formulation consists of DMEM-F12 basal medium, insulin, transferrin, selenium, from about 0.2% to about 2.5% of fatty-acid free albumin, from about 5 ng/ml to about 10 ng/ml of a TGF-β ligand, from about 50 ng/ml to about 100 ng/ml of bFGF, from about 10 ng/ml to about 50 ng/ml of IGF-1 and from about 0.2 mM to about 0.3 mM of ascorbic acid.